期刊文献+

尼可地尔联合氯吡格雷治疗冠心病患者的效果及对血清Lp(a)、CX3CL1水平的影响 被引量:20

Effects of nicorandil combined with clopidogrel on the serum levels of Lp(a),CX3CL1 of patients with coronary heart disease
下载PDF
导出
摘要 目的探究尼可地尔联合氯吡格雷治疗冠心病患者的效果及对血清脂蛋白(a)[Lp(a)]、CX3CL1水平的影响。方法冠心病患者90例随机分为对照组和观察组。对照组使用尼可地尔治疗,观察组在对照组基础上联合氯吡格雷治疗。比较2组治疗后的临床疗效和不良反应发生情况。检测比较治疗前后2组患者的心功能指标[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)]、心电图指标(ST段压低发生次数、ST段压低时间)、血清Lp(a)、CX3CL1水平。结果观察组的有效率显著高于对照组(P<0.05)。治疗后2组心功能指标和心电图指标均得到显著的改善(P<0.05),治疗后观察组的LVEF均显著高于对照组,LVEDD显著低于对照组(P<0.05);治疗后观察组ST段压低发生次数及ST段压低时间均显著低于对照组(P<0.05)。治疗前2组血清CX3CL1、Lp(a)差异无统计学意义(P>0.05),治疗后均显著降低(P<0.05),治疗后观察组血清CX3CL1、Lp(a)均显著低于对照组(P<0.05)。2组的不良反应发生情况差异无统计学意义(P>0.05)。结论尼可地尔联合氯吡格雷,对冠心病具有更好的临床疗效,可更好的改善心脏功能并减少心电图ST段异常。同时联合用药可更有效的降低CX3CL1以及Lp(a)水平,提示联合治疗具有更好的预后。 Objective To investigate the therapeutic effects of nicorandil combined with clopidogrel on coronary heart disease (CHD) and their effects on the serum levels of Lp(a) and CX3CL1 of patients with CHD. Methods A total of 90 patients with CHD who were tyreated in our hospital from March 2017 to March 2018 were randomly divided into control group and observation group.The patients in control group were treated by nicorandil,however,the patients in observation group,on the basis of control group, were treated by clopidogrel.The clinical efficacy and adverse reactions after treatment were observed and compared between the two groups.The cardiac function indexes including gram index, LVEF,LVEDD,ECG indexes including the frequency of ST segment depression and ST segment depression time as well as the serum levels Lp(a) and CX3CL1 before and after treatment were observed and compared between the two grousp. Results The effective rate in observation group was significantly higher than that in control group ( P <0.05).After treatment,the cardiac function indexes and ECG indexes were significantly improved in both groups ( P <0.05).After treatment,the LVEF in observation group was significantly higher than that in control group,however, the LVEDD was significantly lower than that in control group ( P < 0.05 ).After treatment,the frequency of ST-segment depression and the ST-segment depression time in observation group were significantly lower than those in control group ( P <0.05).Before treatment there were no significant differences in the serum levels of CX3CL1 and Lp(a) between the two groups ( P >0.05).After treatment,the serum levels of CX3CL1 and Lp(a) were significantly decreased in both groups,moreover,which in observation group were significantly lower than those in control group ( P <0.05).There was no significant difference in the incidence of adverse reactions between the two groups ( P > 0.05 ). Conclusion The nicorandil combined with clopidogrel has a better clinical curative effects on coronary heart disease
作者 陆爱民 刘宝宝 陈蓉 LU Aimin;LIU Baobao;CHEN Rong(Department of Coronary Heart Diseases, Qinghai Provincial Cardiovascular and Cerebrovascular Disease Hospital,Qinghai,Xining 810000,China)
出处 《河北医药》 CAS 2019年第10期1542-1545,共4页 Hebei Medical Journal
关键词 冠心病 尼可地尔 氯吡格雷 趋化因子CX3CL1 脂蛋白(a) coronary heart disease nicorandil clopidogrel CX3CL1 Lp(a)
  • 相关文献

参考文献7

二级参考文献62

  • 1白书玲,李建军.C反应蛋白与动脉粥样硬化[J].中华心血管病杂志,2004,32(8):765-768. 被引量:133
  • 2周北凡.中国人群心血管病危险因素作用特点的前瞻性研究[J].中华流行病学杂志,2005,26(1):58-61. 被引量:122
  • 3王薇,赵冬,孙佳艺,王文化,成君,刘军,秦兰萍,刘飒,吴兆苏.中国11省市队列人群危险因素与不同类型心血管病发病危险的比较[J].中华心血管病杂志,2006,34(12):1133-1137. 被引量:119
  • 4无.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206. 被引量:2087
  • 5杨水祥,胡大一.以社区为中心加强我国中青年冠心病及猝死的防治[J].中国心血管病研究,2007,5(8):561-563. 被引量:28
  • 6Fihn SD, Gardin JM, Abrams J, et al.2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons[J].Circulation, 2012,126:e354-e471. 被引量:1
  • 7Fihn SD, Gardin JM, Abrams J, et al.2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons[J].Circulation, 2012,126:3097-3137. 被引量:1
  • 8Task force members, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology[J].Eur Heart J, 2013,34:2949-3003. 被引量:1
  • 9Qaseem A, Fihn SD, Williams S, et al.Diagnosis of stable ischemic heart disease: summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons[J].Ann Intern Med 2012;157:729-734. 被引量:1
  • 10江苏省老龄工作委员会办公室.江苏省2013年老年人口信息和老龄事业发展状况报告[EB/OL].http://www.cncaprc.gov.cn/news/52635.jhtml,2014-10-14. 被引量:2

共引文献369

同被引文献224

引证文献20

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部